Redx Pharma Plc announced the appointment of Dr. Andrew Saunders as Chief Medical Officer (CMO). Andrew has worked in the oncology field for over 25 years and has extensive experience in all aspects of the clinical development of oncology drugs. Andrew will work with the research and development team at Redx, fronting the clinical development of RXC004, the company's lead drug candidate. RXC004 is a novel, oral, potent small molecule Porcupine inhibitor, which targets the Wnt signalling pathway and is due to commence phase 1 clinical trials in the coming weeks. Andrew joins Redx from Lytix Biopharma, where he was CMO.